Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
Core Scientific Inc. (CORZ) PT Lowered to $25 at Cantor Fitzgerald on Lowered Mining Value
-
Quantum Computing, Inc. (QUBT) PT Lowered to $10 at Cantor Fitzgerald
-
Streamex names former Cantor Fitzgerald CEO to board
-
Streamex appoints former Cantor Fitzgerald CEO to board
-
Streamex Corp. Appoints Shawn Matthews, Former CEO of Cantor Fitzgerald & Co. & Founder and CIO of Hondius Capital Management, to Board of Directors
-
Streamex Corp. Appoints Shawn Matthews, Former CEO of Cantor Fitzgerald & Co. & Founder and CIO of Hondius Capital Management, to Board of Directors
-
Riot Platforms (RIOT) PT Lowered to $29 at Cantor Fitzgerald on Slack Mining Economics
-
BigBear.ai Holdings (BBAI) PT Lowered to $5 at Cantor Fitzgerald on Market Contraction
-
HubSpot Inc (HUBS) PT Raised to $325 at Cantor Fitzgerald; Fundamentals Underestimated
-
MongoDB (MDB) PT Lowered to $378 at Cantor Fitzgerald on Lower Software Multiples
-
Moonlake Immunotherapeutics (MLTX) Reiterated at Overweight by Cantor Fitzgerald
-
Ouster (OUST) Reiterated at Overweight by Cantor Fitzgerald: Best Positioned in LiDAR
-
Form X-17A-5 CANTOR FITZGERALD & CO. For: Dec 31
-
Form SCHEDULE 13D/A M3-Brigade Acquisition Filed by: CANTOR FITZGERALD & CO.
-
Cantor Fitzgerald Downgrades uniQure BV (QURE) to Neutral following FDA recommendation
-
Cantor Fitzgerald Reiterates Overweight Rating on Ascendis Pharma (ASND)
-
Form NPORT-P CANTOR FITZGERALD INFRAS For: Dec 31
-
DLA, LLC Appoints Jason Meklinsky as Chief Revenue Officer
-
Rallybio and Candid Therapeutics announce merger agreement
-
Rallybio Corporation and Candid Therapeutics Announce Merger Agreement
-
Block (XYZ) PT Raised to $78 at Cantor Fitzgerald: On Path to a Consistent Track Record
-
Fidelity National Information Services (FIS) PT Lowered to $62 at Cantor Fitzgerald
-
MYR Group (MYRG) PT Raised to $311 at Cantor Fitzgerald Amid Repeatable Growth, Better Risk
-
Sterling Construction (STRL) PT Raised to $482 at Cantor Fitzgerald Amid Sustained Demand
-
MasTec (MTZ) PT Raised to $347 at Cantor Fitzgerald: 'Management's Tone Constructive'
-
Cipher Mining (CIFR) PT Lowered to $24 at Cantor Fitzgerald Amid AI Data Center Transition
-
Terawulf Inc. (WULF) PT Raised to $24 at Cantor Fitzgerald as AI Data Center Pipeline Grows
-
Hut 8 Mining Corp. (HUT) PT Lowered to $68 at Cantor Fitzgerald After Bitcoin Price Drop
-
Palvella Therapeutics raises $230 million in upsized stock offering
-
Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
-
MARA Holdings Inc (MARA) PT Lowered to $11 at Cantor Fitzgerald on Lower Mining Revenue
-
Hudson Pacific Properties (HPP) PT Lowered to $10 at Cantor Fitzgerald After Q4 Results
-
PureCycle Technolgies (PCT) PT Lowered to $14 at Cantor Fitzgerald after Q4 Results
-
Rocket Lab USA (RKLB) PT Raised to $85 at Cantor Fitzgerald After Highest Revenue on Record
-
Aon Corp (AON) Reiterated at Overweight by Cantor Fitzgerald and is Now Top Pick
-
BioMarin Pharmaceutical (BMRN) Reiterated at Overweight by Cantor Fitzgerald After Webinar
-
Cantor Fitzgerald Starts Eikon Therapeutics Inc. (EIKN) at Overweight
-
Cantor Fitzgerald Starts Veradermics (MANE) at Overweight
-
VERAXA Biotech Shareholders Approve Merger and Issuance of New Shares to Voyager Acquisition Corp.
-
Cantor Fitzgerald Reiterates Neutral Rating on Elastic NV. (ESTC) Following Q3 Print
-
Nlight (LASR) PT Raised to $62.50 at Cantor Fitzgerald Following Better-Than-Expected Q4 Results
-
Avepoint Inc. (AVPT) PT Lowered to $15 at Cantor Fitzgerald to Reflect Software Multiple Compression
-
Cantor Fitzgerald: 'We continue to view CoreWeave (CRWV) as a leading AI hyperscaler'
-
GitLab Inc (GTLB) PT Lowered to $30 at Cantor Fitzgerald Amid Increasing Competition
-
Okta, Inc (OKTA) PT Lowered to $100 at Cantor Fitzgerald to Reflect Market Contraction
-
Rocket Lab USA (RKLB) PT Raised to $85 at Cantor Fitzgerald After Highest Revenue Yet
-
PureCycle Technolgies (PCT) PT Lowered to $14 at Cantor Fitzgerald: Thesis Unchanged
-
Gold Reserve Closes Strategic US$75 Million Financing
-
Generate Biomedicines prices IPO at $16 per share
-
Generate Biomedicines, Inc. Announces Pricing of Initial Public Offering

